Spots Global Cancer Trial Database for A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Official Title: A Real-world Observational Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients With Advanced Colorectal Cancer
Study ID: NCT06169202
Study Description
Brief Summary: This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer.
Detailed Description: This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer..The purpose of the study is exploring the real-world efficacy and safety of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with metastatic colorectal adenocarcinoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Hospital of China Medical University, Shenyang, Liaoning, China
Contact Details
Name: Yunpeng Liu, PhD
Affiliation: First Hospital of China Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
